The hamartomatous polyposis syndromes are a heterogeneous group of disorders that share an autosomal-dominant pattern of inheritance and are characterized by hamartomatous polyps of the ...

Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal antiinflammatory drugs may be related ...

Juvenile polyposis syndrome is a condition transmitted from parents to offspring, which causes the development of juvenile polyps inside the large intestine, stomach, or throughout the ...

Fast Track designation from the US FDA highlights the potential of eRapa to address a significant unmet medical need in treating Familial Adenomatous Polyposis (FAP), potentially expediting its ...

Patients with germline pathogenic variants (PVs) in APC develop tens (attenuated familial adenomatous polyposis [AFAP]) to innumerable (classic FAP) adenomatous polyps in their colon and are at ...

Familial adenomatous polyposis (FAP) is a hereditary disease which, in addition to a high risk of bowel cancer, also a greatly increased risk of duodenal cancer. At present, the only treatment ...

Lorpucitinib (JNJ-64251330) in patients with familial adenomatous polyposis (FAP): Results from a phase 1b study. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...

Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

Diagnosis Duodenal neuroendocrine neoplasm showing gastrin expression and stage III (T3N2M0), poorly differentiated adenocarcinoma of the cecum arising from hyperplastic polyposis. Management ...

Therapyx Inc.’s Fapxil has been awarded orphan drug designation by the FDA for the treatment of familial adenomatous polyposis (FAP). BioWorld Science Regulatory Gastrointestinal Genetic/congenital ...